Retrorectal cystic hamartomas are rare congenital lesions that can undergo malignant transformation, and adenocarcinoma is the most frequently described histological type. The authors describe a case of a 53-year-old female patient with a localized well-differentiated adenocarcinoma that developed in a retrorectal cystic hamartoma. The patient was submitted to surgery (a Kraske procedure), with an R1 resection, followed by adjuvant radio-chemotherapy. After 23 months of follow up, the patient remains free from disease recurrence. Given the rarity of this entity, this case allows us to reflect on the differential diagnosis, therapeutic approach and patients' follow-up.
Introduction
Retrorectal cystic hamartomas (RCH), or tailgut cysts, are rare congenital presacral lesions that arise from an aberrant remnant of postnatal hindgut due to incomplete involution during embryological development [1] . According to the literature, malignant transformation of the epithelial or stromal components of RCH may occur in up to 14% of patients [2] . Adenocarcinoma is the most frequently described histological type, followed by carcinoid tumors [2] [3] [4] [5] .
It is most common in middle-aged women and usually is discovered incidentally or on the study of pain, rectal bleeding, or symptoms related to mass effect on the rectum or bladder [6] . Magnetic resonance imaging (MRI) is the most use-ful exam for diagnosis and preoperative planning [7] . Biopsy should be performed in unresectable or locally advanced cases, in order to define the best therapeutic strategy [2] .
Complete surgical resection is the standard treatment if possible [3] . Systemic treatment depends on histology and stage. Adjuvant radio-chemotherapy and palliative chemotherapy including 5-fluorouracil and leucovorin have been reported for adenocarcinomas [8] [9] [10] [11] .
Prognosis for RCH with malignant transformation depends on complete surgical resection, tumour histology and grade, with local recurrences and distant metastasis occasionally reported [12] . Follow-up is clinical, with imaging according to clinical history and examination [12] .
The authors describe a case of a 53-year-old female patient with a localized well-differentiated adenocarcinoma that developed in a retrorectal cystic hamartoma, after obtaining her consent. Given the rarity of this entity, we aimed to reflect on questions such as the differential diagnosis, therapeutic approach and patients' follow-up. Figure 5 . Radiotherapy planning in the sagittal (6) and axial plan (7) , to give 45 Gy to the regional lymph nodes and 54 Gy to the surgical bed and sacrum, 1.8 Gy per fraction, through Intensity Modulated Radiation Therapy. 
Case Report

Discussion
RCH have an estimated overall incidence of 1 in 40,000, but more frequent imaging exams and advances in diagnostic techniques are leading to an increased identification of cases [13] [14] .
Malignant transformation of RCH to adenocarcinoma was first described in 1931 [15] . Although rare, malignancy was described in up to 14% of patients with RCH, enhancing the importance of the inclusion of this entity in the differential diagnosis of a retrorectal mass [2] . These lesions should be distinguished from others which may occur in that localization, such as teratomas, epidermal cysts, rectal duplication cysts, anal gland cysts and anal gland carcinomas.
MRI is the most helpful investigation exam, with a diagnostic accuracy of 100% in defining the lesion, and a reported positive predictive value of 100% for malignancy [12] . The preoperative biopsy for RCH is controversial, especially with the improvement in the imaging tools and also due to biopsy-related complications such as infection, hematoma, and needle track implants [16] . However, in this case where the concern about malignant degeneration was high, the advantage was that it could help with optimal planning of surgical approach and adjuvant therapy, and also in the information about prognosis.
Complete surgical excision is the therapy of choice and the most common surgical approach described is via a posterior para-sacral incision, particularly for lesions below the level of S3 or the sacral promontory [6] . This approach is safe and is associated with low risk of local recurrence, although fistulas to the rectum may be more common than in others situations [3] . Unfortunately, in this case surgery was R1, as the upper and anterior margins of the soft tissues were positive. The sacral bone margins were not involved, which reinforces the relevance of the trans-sacral resection. Attending to histological type and localization of these tumours, we should debate if there is a place for preoperative radio-chemotherapy to improve R0 resections, in analogy to what is performed in rectal cancers.
Because of the small number of patients with malignancy in published series of RCH, no significant conclusions can be drawn regarding local or distant recurrence [3] . According to histology and R1 surgery, our patient was proposed for complementary treatment with radio-chemotherapy, remaining without evidence of disease after approximately two years of follow-up. Nevertheless, the patient is being closely monitored, clinically and with radiological exams. In case of unresectable local recurrence or distant metastasis, and although only palliative chemotherapy including 5-fluorouracil and leucovorin have been reported, maybe we should consider association regimens, such as with oxaliplatin or irinotecan, according to what is done, nowadays, in colorectal tumours.
Conclusion
RCH with malignant transformation should be considered in the differential diagnosis of a retrorectal mass. After a trimodal treatment, our patient is being closely 
